Status:
COMPLETED
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
Lead Sponsor:
Taejoon Pharmaceutical Co., Ltd.
Conditions:
Primary Open-angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not ...
Eligibility Criteria
Inclusion
- Male or female, age 19 or over
- Written informed consent to participate in the trial
Exclusion
- Any other Galucoma except POAG(ex, Closed anterior chamber angle, angle-closure glaucoma)
- Any laser or ocular surgery within 3months prior screening
- Use of contact lenses
- Known reactive airways disease
- Any condition limiting patient's ability to participate in the trial
Key Trial Info
Start Date :
April 26 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT03419975
Start Date
April 26 2016
End Date
June 1 2018
Last Update
September 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chan Yun, Kim
Seoul, South Korea